PCSK9 Inhibitors and Neurocognitive Adverse Drug Reactions: Analysis of Individual Case Safety Reports from the Eudravigilance Database
出版年份 2020 全文链接
标题
PCSK9 Inhibitors and Neurocognitive Adverse Drug Reactions: Analysis of Individual Case Safety Reports from the Eudravigilance Database
作者
关键词
-
出版物
DRUG SAFETY
Volume -, Issue -, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2020-12-22
DOI
10.1007/s40264-020-01021-3
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Indirect comparison of the efficacy and safety of alirocumab and evolocumab: a systematic review and network meta-analysis
- (2020) Paul Guedeney et al. European Heart Journal-Cardiovascular Pharmacotherapy
- PCSK9 in Haemostasis and Thrombosis: Possible Pleiotropic Effects of PCSK9 Inhibitors in Cardiovascular Prevention
- (2019) Francesco Paciullo et al. THROMBOSIS AND HAEMOSTASIS
- Evaluating the efficacy and safety of atorvastatin + ezetimibe in a fixed-dose combination for the treatment of hypercholesterolemia
- (2019) Ya-Bin Ma et al. EXPERT OPINION ON PHARMACOTHERAPY
- Proprotein Convertase Subtilisin/Kexin Type 9, Brain Cholesterol Homeostasis and Potential Implication for Alzheimer’s Disease
- (2019) Maria Pia Adorni et al. Frontiers in Aging Neuroscience
- PCSK9 Inhibitor Use in the Real World: Data From the National Patient‐Centered Research Network
- (2019) Alanna M. Chamberlain et al. Journal of the American Heart Association
- Preventable Cases of Oral Anticoagulant-Induced Bleeding: Data From the Spontaneous Reporting System
- (2019) Annamaria Mascolo et al. Frontiers in Pharmacology
- Efficacy and safety of alirocumab and evolocumab: a systematic review and meta-analysis of randomized controlled trials
- (2019) Paul Guedeney et al. EUROPEAN HEART JOURNAL
- Association between Thyroid-Stimulating Hormone Level after Total Thyroidectomy and Hypercholesterolemia in Female Patients with Differentiated Thyroid Cancer: A Retrospective Study
- (2019) Young Ki Lee et al. Journal of Clinical Medicine
- Proprotein convertase subtilisin/kexin type 9 (PCSK9) in Alzheimer’s disease: A genetic and proteomic multi-cohort study
- (2019) Cynthia Picard et al. PLoS One
- Long-Term Efficacy and Safety of Evolocumab in Patients With Hypercholesterolemia
- (2019) Michael J. Koren et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Health Care Professionals’ Knowledge, Attitude, and Practice towards Adverse Drug Reaction Reporting and Associated Factors at Selected Public Hospitals in Northeast Ethiopia: A Cross-Sectional Study
- (2019) Belete Kassa Alemu et al. Biomed Research International
- Safety of Proprotein Convertase Subtilisin/Kexin Type 9 Monoclonal Antibodies in Regard to Diabetes Mellitus: A Systematic Review and Meta-analysis of Randomized Controlled Trials
- (2019) Qiwen Chen et al. American Journal of Cardiovascular Drugs
- PCSK9 Inhibitors’ New Users: Analysis of Prescription Patterns and Patients’ Characteristics from an Italian Real-world Study
- (2019) Carlo Piccinni et al. CLINICAL DRUG INVESTIGATION
- Prescribing Patterns of Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors in Eligible Patients With Clinical Atherosclerotic Cardiovascular Disease or Heterozygous Familial Hypercholesterolemia
- (2018) Dean G. Karalis et al. AMERICAN JOURNAL OF CARDIOLOGY
- Efficacy and Safety of Ezetimibe and Rosuvastatin Combination Therapy Versus Those of Rosuvastatin Monotherapy in Patients With Primary Hypercholesterolemia
- (2018) Woohyeun Kim et al. CLINICAL THERAPEUTICS
- PCSK9 inhibition in the management of familial hypercholesterolemia
- (2018) Masatsune Ogura Journal of Cardiology
- Long-term efficacy and safety of proprotein convertase subtilisin/kexin 9 monoclonal antibodies: A meta-analysis of 11 randomized controlled trials
- (2018) Jie Bai et al. Journal of Clinical Lipidology
- Adverse Events Associated With PCSK9 Inhibitors: A Real-World Experience
- (2018) Muhammed T. Gürgöze et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Sex differences in lipid metabolism are affected by presence of the gut microbiota
- (2018) Annemarie Baars et al. Scientific Reports
- Did the New Italian Law on Mandatory Vaccines Affect Adverse Event Following Immunization’s Reporting? A Pharmacovigilance Study in Southern Italy
- (2018) Cristina Scavone et al. Frontiers in Pharmacology
- Real-world treatment patterns of PCSK9 inhibitors among patients with dyslipidemia in Germany, Spain, and the United Kingdom
- (2018) Ming-Hui Tai et al. CURRENT MEDICAL RESEARCH AND OPINION
- Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
- (2018) Gregory G. Schwartz et al. NEW ENGLAND JOURNAL OF MEDICINE
- No evidence of neurocognitive adverse events associated with alirocumab treatment in 3340 patients from 14 randomized Phase 2 and 3 controlled trials: a meta-analysis of individual patient data
- (2017) Philip D Harvey et al. EUROPEAN HEART JOURNAL
- Cognitive Function in a Randomized Trial of Evolocumab
- (2017) Robert P. Giugliano et al. NEW ENGLAND JOURNAL OF MEDICINE
- Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
- (2017) Marc S. Sabatine et al. NEW ENGLAND JOURNAL OF MEDICINE
- Identification of a Syndrome Class of Neuropsychiatric Adverse Reactions to Mefloquine from Latent Class Modeling of FDA Adverse Event Reporting System Data
- (2017) Remington L. Nevin et al. Drugs in research & development
- Increased Risk of Adverse Neurocognitive Outcomes With Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors
- (2017) Abdur Rahman Khan et al. Circulation-Cardiovascular Quality and Outcomes
- Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease
- (2017) Marc P. Bonaca et al. CIRCULATION
- The value of patient reporting to the pharmacovigilance system: a systematic review
- (2016) Pedro Inácio et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- PCSK9 Inhibitors and Neurocognitive Adverse Events: Exploring the FDA Directive and a Proposal for N-of-1 Trials
- (2015) Kristopher J. Swiger et al. DRUG SAFETY
- Emerging PCSK9 inhibitors for treating dyslipidaemia: buttressing the gaps in coronary prevention
- (2015) Michael M Page et al. EXPERT OPINION ON EMERGING DRUGS
- Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
- (2015) Jennifer G. Robinson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events
- (2015) Marc S. Sabatine et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dyslipidemia and Cardiovascular Disease in Women
- (2015) Renata Cífková et al. Current Cardiology Reports
- Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: Rationale and design of the ODYSSEY Outcomes trial
- (2014) Gregory G. Schwartz et al. AMERICAN HEART JOURNAL
- Cardiovascular risk factors and future risk of Alzheimer’s disease
- (2014) Renée FAG de Bruijn et al. BMC Medicine
- Neuropsychiatric Adverse Events Associated with Statins: Epidemiology, Pathophysiology, Prevention and Management
- (2014) Marco Tuccori et al. CNS DRUGS
- Efficacy and Safety of Longer-Term Administration of Evolocumab (AMG 145) in Patients With Hypercholesterolemia
- (2013) Michael J. Koren et al. CIRCULATION
- The effects of laropiprant on the antiplatelet activity of co-administered clopidogrel and aspirin
- (2013) Pieter-Jan De Kam et al. PLATELETS
- Attitudes among healthcare professionals to the reporting of adverse drug reactions in Nepal
- (2013) Santosh KC et al. BMC Pharmacology & Toxicology
- The effect of a platelet cholesterol modulation on the acetylsalicylic acid-mediated blood platelet inhibition in hypercholesterolemic patients
- (2011) Boguslawa Luzak et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Sex Differences in Lipid and Lipoprotein Metabolism: It's Not Just about Sex Hormones
- (2011) Xuewen Wang et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- PCSK9 is not involved in the degradation of LDL receptors and BACE1 in the adult mouse brain
- (2010) Mali Liu et al. JOURNAL OF LIPID RESEARCH
- PCSK9 is required for the disposal of non-acetylated intermediates of the nascent membrane protein BACE1
- (2008) Mary Cabell Jonas et al. EMBO REPORTS
- Gender differences in the lipid profile of dyslipidemic subjects
- (2008) Genovefa D. Kolovou et al. European Journal of Internal Medicine
- PCSK9: a convertase that coordinates LDL catabolism
- (2008) Jay D. Horton et al. JOURNAL OF LIPID RESEARCH
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started